发明名称 |
Use of cannabinoids in the treatment of epilepsy |
摘要 |
Cannabidiolic acid (CBDA) for use in the treatment of epilepsy, preferably where the epilepsy is a generalised epilepsy characterised by tonic-clonic seizures. Preferably the CBDA is in the form of a highly purified extract of cannabis such that the CBDA is present at greater than 98% of the total extract (w/w) and comprises less than 1% (w/w) tetrahydrocannabinol (THC) or tetrahydrocannabinol acid (THCA). The CBD may be synthetically produced. The CBDA may be used with cannabidiol (CBD) preferably where the CBDA:CBD ratio is in the range from 9:1 to 1:9 (CBDA:CBD). Preferably the CBD is used at a dose of from 1mg-100mg. |
申请公布号 |
GB2541191(A) |
申请公布日期 |
2017.02.15 |
申请号 |
GB20150014079 |
申请日期 |
2015.08.10 |
申请人 |
GW Pharma Limited |
发明人 |
Colin Stott;Nicholas Jones;Robin Williams;Benjamin Whalley |
分类号 |
A61K31/192;A61K36/185;A61P25/08;A61P25/12 |
主分类号 |
A61K31/192 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|